The third group contains four mitotic proteins (ANAPC5, CDC16, CDC20, CDC27) and shRNAs targeting these mitotic genes are predicted to sensitize cancer cells to GSK461364A [Table 1]. This evidence concerns the gene CDC16 and cancer.